Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease

about

Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease

Item

http://www.wikidata.org/entity/Q57067878

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Interleukin 12/interleukin 23 ...... patients with Crohn's disease

@en

Interleukin 12/interleukin 23 ...... patients with Crohn's disease

@nl

type

Item

label

Interleukin 12/interleukin 23 ...... patients with Crohn's disease

@en

Interleukin 12/interleukin 23 ...... patients with Crohn's disease

@nl

prefLabel

Interleukin 12/interleukin 23 ...... patients with Crohn's disease

@en

Interleukin 12/interleukin 23 ...... patients with Crohn's disease

@nl

P1476

Interleukin 12/interleukin 23 ...... patients with Crohn's disease

@en

P2093

Christos Konstantakis

http://www.w3.org/2001/XMLSchema#string

Christos Triantos

http://www.w3.org/2001/XMLSchema#string

Ioanna Aggeletopoulou

http://www.w3.org/2001/XMLSchema#string

Stelios F Assimakopoulos

http://www.w3.org/2001/XMLSchema#string

P2860

IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12

Interleukin-23 drives innate and T cell-mediated intestinal inflammation

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Certolizumab pegol for the treatment of Crohn's disease

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

Crohn's disease

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q

P304

4093-4103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3748/WJG.V24.I36.4093

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30271076

http://www.w3.org/2001/XMLSchema#string

P921

gastroenterology

interleukin

P932

6158482

http://www.w3.org/2001/XMLSchema#string